hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.
hVIVO appoints Nominated Adviser and Joint Broker
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026.
hVIVO partners with ILiAD Biotechnologies for the first-ever Phase 3 human challenge trial of BPZE1, a next-gen Bordetella pertussis vaccine.
hVIVO plc (LON:HVO) secures its largest £3.2M hLAB contract, expanding lab capacity and supporting a major Phase 2 study for a US biotech firm.
hVIVO plc's hLAB signs a £2.7m contract to lead virology services for a US biotech's Phase 2 influenza study, marking its largest deal yet.
hVIVO plc, a leading CRO, successfully completes a pilot study for hMPV challenge trials, paving the way for new vaccines and antivirals.
hVIVO plc announces a breakthrough in identifying biomarkers for respiratory infections, published in Nature Communications, advancing diagnostics and patient care.
